There is a low risk of [serious ocular side effects], says co-author Andrew Morgenstern, O.D., director of the AOAs clinical resources group
Ania Jastreboff, an obesity medicine physician scientist at Yale University School of Medicine/Yale School of Medicine, co-Director of the Yale Center for Weight Management and the lead author on the phase 2 study, said that the results were striking and concluded that Retatrutide holds promise for substantial weight reduction in adults with obesity over a 48-week period
Changing the healthcare landscape With the introduction of these weight loss treatments, pharmaceutical companies face a critical juncture
Emptying of the Gastric Substitute Glucagon-Like-Peptide-1 (GLP-1), and Reactive Hypoglycemia After Total Gastrectomy
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
Premium packaging and branding consistency